Quarterly ResultAug 11, 2026, 07:12 AM
Xtant Medical Q2 Revenue $23.0M, Net Loss $9.4M; Cuts FY26 Guidance
AI Summary
Xtant Medical Holdings, Inc. reported a significant decline in its second quarter 2026 financial results, with total revenue falling to $23.0 million from $35.4 million year-over-year, and a net loss of $9.4 million compared to a net income of $3.6 million in the prior year. The company also reduced its full-year 2026 revenue guidance to a range of $99 million to $103 million. The revenue decline was primarily attributed to the sale of non-core assets and the cessation of certain license revenues, partially offset by new product launches and a distribution agreement for HEMOBLAST® Bellows.
Key Highlights
- Q2 2026 total revenue decreased to $23.0 million from $35.4 million YoY.
- Q2 2026 net loss was $9.4 million, compared to net income of $3.6 million YoY.
- Q2 2026 Non-GAAP adjusted EBITDA loss was $2.7 million, down from $6.9 million positive YoY.
- Gross margin for Q2 2026 was 57.9%, down from 68.6% YoY.
- Full-year 2026 revenue guidance reduced to $99 million-$103 million from $101 million-$105 million.
- Cash and cash equivalents were $9.9 million as of June 30, 2026.
- Total indebtedness was $23.0 million as of June 30, 2026.
Price Impact
More from XTNT